We are delighted to announce that our abstract has been accepted for poster presentation (display) at the ESMO Immuno-Oncology Congress 2022, Geneva, Switzerland 7-9 December 2022. The presentation is supported by the presence of Company employees and the Principal Investigator for the trial.
Abstract # 514; A Phase I Study of the cancer-specific vaccine FMPV-1 in Healthy Male Subjects to Assess Safety and Immune Response
Hope to see you there!